Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ Capital MarketTotal Valuation
Telomir Pharmaceuticals, Inc. Common Stock carries a market capitalization of 42.29M, placing it among publicly traded companies globally.
| Market Cap | 42.29M |
| Enterprise Value | N/A |
Share Statistics
Telomir Pharmaceuticals, Inc. Common Stock currently has 34.38M shares outstanding.
| Shares Outstanding | 34.38M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -1.00 |
| P/TBV Ratio | 8.45 |
| P/FCF Ratio | -9.12 |
| P/OCF Ratio | -9.12 |
Financial Position
Telomir Pharmaceuticals, Inc. Common Stock maintains a current ratio of 7.00, meaning it holds 7.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 7.00 |
| Quick Ratio | 6.72 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -7,768.74 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -293.73 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Telomir Pharmaceuticals, Inc. Common Stock's stock has declined approximately -41.70616% over the past 52 weeks. The 50-day moving average sits at 1.31, while the 200-day moving average is 1.36.
| Beta (5Y) | N/A |
| 52-Week Price Change | -41.70616% |
| 50-Day Moving Average | 1.31 |
| 200-Day Moving Average | 1.36 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -9.39M, while operating income came in at -9.39M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -9.39M |
| Pretax Income | -9.22M |
| Net Income | -9.22M |
| EBITDA | -9.39M |
| EBIT | -9.39M |
| Earnings Per Share (EPS) | -0.29 |
Balance Sheet
Total book value stands at -42.00M, with working capital of 4.96M providing operational flexibility.
| Cash & Cash Equivalents | 5.56M |
| Total Debt | N/A |
| Net Debt | -5.56M |
| Equity (Book Value) | -42.00M |
| Book Value Per Share | -1.30 |
| Working Capital | 4.96M |
Cash Flow
Telomir Pharmaceuticals, Inc. Common Stock produced -4.60M in operating cash flow over the past twelve months.
| Operating Cash Flow | -4.60M |
| Capital Expenditures | N/A |
| Free Cash Flow | -4.60M |
| FCF Per Share | -0.14 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -23.26 |
| FCF Yield | -10.96 |
Scores
Telomir Pharmaceuticals, Inc. Common Stock posts an Altman Z-Score of 15.94, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 15.94 |